Apyx Medical Q2 revenue $13.9M (+22% YoY); Surgical Aesthetics up 28%; reaffirms FY guidance

Apyx Medical Corp

Total revenue $13.9M vs $11.4M in Q2 2025; Surgical Aesthetics segment grew 28% to $12.4M.
Net loss narrowed to $3.2M ($0.07/sh) from $3.8M ($0.09/sh); Adjusted EBITDA loss improved to $0.7M from $2.0M.
Reaffirmed FY2026 revenue guidance $59.0M-$60.0M; Surgical Aesthetics expected $54.0M-$55.0M.
Limited commercial launch of power liposuction handpiece for AYON platform began in June 2026 after FDA clearance.
Cash and equivalents $27.6M; management expects to yield cash through 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.